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The introduction of any new technology necessi-
tates careful observation. This is particularly so with
technology that involves an implantable prosthesis.
The Food and Drug Administration requires the
reporting of all adverse events in trial protocols.1 An
adverse event is any undesirable clinical occurrence
that necessitates medical treatment or intervention
in a patient.2 Adverse events may be related to pro-
cedure or to other patient conditions. We present
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Purpose: The aim of this study was to document the incidence rate of adverse events after
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Methods: One hundred ninety patients (175 men, 15 women; mean age, 72 years) under-
went endoluminal repair of AAAs in a 51⁄2-year period. Adverse events were document-
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defined as any of the following events: a death within 30 days, a conversion to open
repair, the need for further intervention (either open or endovascular), the need for
hemodialysis, a failure to cure the AAA, and wound complications. The patients were
divided into two groups—those who underwent operation in the initial 3-year period
(group I; n = 75) and those who underwent operation in the subsequent 21 ⁄ 2-year peri-
od (group II; n = 115). The results were analyzed for total adverse events for both peri-
ods of time and for difference in incidence rates within categories of adverse events
between the two groups. 
Results: Eight patients (4.2%) died in the perioperative period. The endoluminal repair
failed in 17 patients (8.9%), which necessitated a primary conversion to open repair at
the original operation. In 88 patients, 110 adverse events occurred. There was no sig-
nificant difference in the incidence rates of adverse events in patients in group I (37/75)
and group II (51/115). Apart from primary conversion (P = .007), there was no sig-
nificant difference in the incidence rates of adverse events between group I and group II
within the following categories: perioperative (within 30 days) deaths, primary conver-
sion, secondary conversion, supplementary endoluminal repair, intervention for lower
limb ischemia, hemodialysis necessitated, failure to cure the AAA as a result of persistent
endoleak, and wound complications.
Conclusion: Despite improvements in technology and increasing experience, adverse
events continue to occur in a relatively high proportion of patients (45%) who undergo
endoluminal repair of AAA. Reporting the incidence rates of adverse events provides a
more accurate picture of the morbidity rates of the endoluminal method rather than sim-
ply listing the procedures as successes or failures. The similarity in the incidence rates of
adverse events in patients in group I and group II suggests that there are inherent risks
in the endoluminal method rather than iatrogenic complications that occur during the
learning curve with a new technique. (J Vasc Surg 1999;29:32-9.)
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our experience with procedure-related adverse
events that were associated with the endoluminal
repair of abdominal aortic aneurysms (AAAs) in a 
51⁄2-year period.
We previously have reported a high incidence
rate of local/vascular complications after endolumi-
nal AAA repair.3 We also have suggested critical inci-
dent reporting4 during the performance of endolu-
minal aneurysm repair because many of these inci-
dents, like some categories of adverse events, would
not necessarily be listed as complications in a case
that was deemed to be successful.
With improvements in technology and increas-
ing experience with this method of repair, it could
be anticipated that the incidence rate of adverse
events would decrease with time. To test this
hypothesis, we documented the incidence rate of
adverse events after endoluminal repair of AAA dur-
ing two successive periods of time.
METHODS
One hundred ninety patients (175 men, 15
women; mean age, 72 years) underwent primary
endoluminal repair of true AAA at the Royal Prince
Alfred Hospital between May 1992 and November
1997. Twelve patients who underwent secondary
endoluminal repair of AAA and two patients who
underwent repair of false aneurysm were excluded
from the study. Adverse events were documented
prospectively for all the patients throughout this
51⁄2-year period. An adverse event was defined as any
of the following events: a death within 30 days, a
conversion to open repair, the need for further inter-
vention (either open or endovascular), the need for
hemodialysis, a failure to cure the AAA, and wound
complications.
The patients were divided into two groups—
those who underwent operation in the initial 3-year
period (group I; n = 75) and those who underwent
operation in the subsequent 21⁄2-year period (group
II; n = 115). Patients in both groups were similar
with regard to age, sex, size of aneurysm, and inci-
dence rate of comorbidities. The groups differed in
the extent of tortuosity of the common iliac arteries,
the proportion of first generation endografts used,
and the configuration of the endografts used for
repair. The degree of tortuosity of the common iliac
arteries was 90 or less in all the patients in group I,
and group II contained 20 patients (17%) with tor-
tuosity that exceeded 90 and ranged to 150. Five
patients in group I required end-to-side Dacron
grafts to the common iliac arteries for use as tempo-
rary conduits because of tortuosity and calcifica-
tion.5 The proportion of first to second generation
endografts was 75:0 (100%) in group I and 45:70
(39%) in group II. First and second generation
endografts are listed in Table I.
The ratio of tube grafts to nontube grafts (bifur-
cated and tapered aortoiliac grafts) in group I was
39:36 and in group II was 17:98. The clinical char-
acteristics of the two groups are summarized in
Table II. The results were analyzed for total adverse
events for both periods of time and for difference in
incidence rate within categories of adverse events
between the two groups.
Statistical analysis. The differences in means
were tested with an unpaired t test for independent
continuous variables. The differences in proportion
were tested by c 2 test with a Fisher exact test when
one cell had less than five patients or variables.
RESULTS
Total adverse events in a 51⁄2-year period. One
hundred ten adverse events occurred in 88 patients.
Eight patients (4.2%) died in the perioperative period.
Seven of these eight patients were at high risk and
were considered unfit for conventional open repair.
Fig 1. Aortogram performed 24 hours after endoluminal
abdominal aortic aneurysm repair on one of two patients
in whom renal arteries were inadvertently covered by pros-
thesis. Note the wireforms of prosthesis immediately
below hepatic and splenic arteries and partial filling of
contrast in right renal artery. Reproduced with permission
from the European Journal of Vascular and Endovascular
Surgery 1997;14:4-11.
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The deaths in these seven patients were related to the
following procedures: cardiac death after operation
for lower limb ischemic complication (n = 3), renal
failure as a result of contrast load (n = 2), inadvertent
covering of renal arteries (n = 1), and cardiac death
after operation for balloon rupture of the aorta (n =
1). The one death that occurred in a patient at good
risk was caused by sigmoid volvulus 3 weeks after
endoluminal repair. Endoluminal repair failed in 17
patients (8.9%), who required primary conversion to
open repair at the original operation. Secondary con-
version to open repair was necessary in 10 patients.
Seven of these patients had persistent endoleak; four
of these were urgent with ruptured AAA. Of the
remaining three patients who required secondary
conversion, one had an increasing AAA diameter, but
an exhaustive and repeated investigation failed to
reveal an endoleak. Two had inadvertent covering of
the renal arteries by their prostheses (Fig 1).6 There
were no deaths after secondary conversion, including
four patients with rupture. Supplementary endolumi-
nal repair was undertaken for persistent endoleak on
15 occasions in 12 patients (secondary, n = 12; ter-
tiary, n = 2; and quaternary, n = 1). Further interven-
tion was necessary for lower limb ischemia in 24
patients. In 18 patients, the ischemia was acute and
occurred in the perioperative period, and in six
patients, it was chronic and resulted in claudication
(Fig 2). Interventional procedures for acute and
chronic ischemia are summarized in Table III. Three
patients had peripheral emboli that were treated with
heparin infusion. Hemodialysis after endoluminal
repair was necessitated in seven patients, including the
two patients with inadvertent covering of the renal
arteries. The details of the patients who required dial-
ysis are listed in Table IV.6 Failure to cure the AAA
occurred in 22 patients with persistent endoleaks.
One patient died with an endoleak in the periopera-
tive period. Six endoleaks sealed spontaneously, three
necessitated coil embolization, and two further persis-
tent endoleaks were not treated because of the occur-
rence of unrelated, life-threatening illness. The
remaining 10 patients are under observation with the
potential for further intervention if a spontaneous seal
does not occur.
The wound complications comprised lymph
Table I. Number of prostheses used for endoluminal abdominal aortic aneurysm repair in two groups of
patients who underwent intervention during two successive periods of time
Classification Prosthesis Group I Group II
First generation
Modified Parodi 10 0
White-Yu 52 40
Endovascular Technologies 12 5
Chuter 1 0
Second generation
Stentor Vanguard 0 56
Bard 0 5
Talent 0 4
Baxter 0 2
AneuRx 0 3
Total 75 115
Proportion first generation 75:0 (100%) 45:70 (39%)
Table II. Clinical characteristics of two groups of patients who underwent endoluminal repair of abdomi-
nal aortic aneurysm during two successive periods of time
Group I (n = 75) Group II (n = 115) P value
Age (mean in years) 71 72 NS
Female/male 6/69 9/106 NS
AAA diameter (mean in cm) 5.5 5.4 NS
Comorbidities 44% 30% NS
Common iliac tortuosity (>90 degrees/90 degrees or less) 0/75 20/95 .00002
Proportion first generation prostheses 75/0 45/70 <.000001
Configuration tube/nontube grafts 39/36 17/98 <.00001
AAA, Abdominal aortic aneurysm.
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leak/lymphocele (n = 5), hematoma (n = 4), and
infection (n = 3). The infections were staphylococcal
and involved the subcutaneous tissue but not the
underlying vessels. Of the 12 patients with wound
complications, only one with persistent lymph leak
required a secondary operation. Hospital stay was
prolonged beyond 10 days in two patients with
infection and lymph leak, respectively.
The incidence rates of adverse events varied for
different prostheses, but the differences were not
significant (Table V).
The comparison of adverse events occurred dur-
ing two successive periods of time.
There was no significant difference in the inci-
dence rates of adverse events in patients in group I
(48/75; 64%) and group II (62/115; 54%). Apart
from primary conversion (P = .007), there was no
significant difference in the incidence rates of
adverse events between group I and group II within
the following categories: perioperative (within 30
days) deaths, primary conversion, secondary conver-
sion, supplementary endoluminal repair, interven-
tion for lower limb ischemia, hemodialysis necessi-
tated, failure to cure the AAA as a result of persistent
endoleak, and wound complications (Table VI).
DISCUSSION
At the Joint Meeting of the Society for Vascular
Surgery and the North American Chapter of the
International Society for Cardiovascular Surgery in
1997, we presented a 5-year experience with endo-
luminal AAA repair.7 Analysis was with the life-table
method and included all the patients from the out-
set of the program. We received, with some justifica-
tion, criticism that the graft success probability of
70% at 3 years did not accurately reflect the current
situation because improved second generation pros-
theses had now replaced the earlier models. This
served as a stimulus for us to compare the perfor-
mance of the devices and the operators in two con-
secutive periods of time.
Somewhat to our surprise, we found no signifi-
Fig 2. Contrast computed tomographic scan showing
occlusion in right limb of bifurcated prosthesis 3 months
after endoluminal abdominal aortic aneurysm repair. Note
absence of contrast compared with patent left limb.
Fig 3. Contrast computed tomographic scan showing
endoleak 1 year after endoluminal repair of abdominal
aortic aneurysm with bifurcated prosthesis. Note the right
ipsilateral limb of prosthesis is circular in cross-section,
which indicates a vertical disposition, and the left con-
tralateral limb is lying transversely, having become dislo-
cated from contralateral stump. Reproduced with permis-
sion from Advances in Vascular Surgery, St Louis, Mo:
Mosby, Inc.
Table III. Procedures performed in the manage-
ment of acute and chronic ischemia of the lower
extremity after endoluminal abdominal aortic
aneurysm repair
Procedure Acute ischemia Claudication
Iliofemoral graft 5
Femorofemoral graft 4 2
Embolectomy 2
Endovascular stent alone 2 3
Endovascular stent + 
iliofemoral graft 1
Endovascular stent + 
femorofemoral graft 1
Endovascular stent + 
femoropopliteal graft 1
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cant difference in the incidence rates of total adverse
events in patients who underwent treatment in the
early and later periods of time. Likewise, no signifi-
cant difference was found between the individual
categories of adverse events in the two time periods,
with the exception of primary conversion from
endoluminal to open repair, which occurred more
frequently in the early period.
There are some possible explanations for this para-
doxical situation in which improvements in technolo-
gy and increasing experience have failed to reduce the
incidence rate of adverse events. New equipment may
simply replace an old problem with a new problem.
Endoleak, for instance, was an uncommon occurrence
with endografts of aortoiliac/femoral configuration in
the early period of time. In some cases, this resulted
from the practice of hand suturing the distal end of the
endograft, which guaranteed freedom from distal
endoleak. With the advent of endografts with self-
expanding metallic frames that ran throughout their
length, hand suturing was no longer necessary. This
had the advantage of being less invasive but the disad-
vantage of increasing the potential for distal endoleak.
Similarly, the modular bifurcated endografts elim-
inated the problem of twisting during deployment of
one-piece bifurcated grafts, which thus reduced the
incidence rate of immediate conversion from endolu-
minal to open repair. Coinciding with this reduction
in need for conversion, however, was a corresponding
increase in the incidence rate of endoleak as a result of
dislocation of component parts of modular prostheses
(Fig 3).
A disproportionately larger number of tube endo-
graft procedures were performed in the early time
period, and a disproportionately larger number of
bifurcated endograft procedures were performed in
the later period. Although this change had the desir-
able effect of reducing the incidence rate of distal
endoleak in patients who had distal aneurysm necks of
marginal or inadequate length and who would previ-
ously have undergone a tube endograft procedure,
the bifurcated endograft brought its own complica-
tions. In particular, kinking and twisting of the limbs
of bifurcated endografts resulted in distal ischemia
and the need for further intervention (Fig 4).
A further factor that mitigated against a reduc-
tion in adverse events is the increasing willingness to
attempt endoluminal repair in patients who are more
technically challenging that accompanies increasing
experience. This factor is largely unrecognized and
difficult to quantify. The most notable example of
this is the comparison of groups I and II in regard to
Table V. Incidence rate of adverse events for dif-
ferent prostheses
Operations Adverse events Percent
White-Yu 102 47 46%
Endovascular 17 7 41%
Technologies
Stentor 14 9 64%
Vanguard 42 26 61%
Table IV. Hemodialysis after endoluminal repair
Group I Group II
(n = 3) (n = 4)
Preoperative renal impairment 1 3
Inadvertent covering of renal arteries 1 1
Temporary dialysis 3 2
Death 1 2
Fig 4. Plain x-ray of abdomen taken in oblique plane 1
year after endoluminal abdominal aortic aneurysm repair
showing kinking of both limbs of bifurcated prosthesis.
Kinking has resulted from diminution in size of aneurysm
sac subsequent to successful repair and has led to occlu-
sion of left contralateral limb.
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degree of tortuosity of the common iliac arteries. In
group I, this did not exceed 90 degrees, whereas
patients in group II frequently had common iliac
arteries with degrees of tortuosity that exceeded 90
degrees and ranged to 150 degrees.
A further analysis of the category of failure to cure
the AAA as a result of persistent endoleak revealed that
16 endoleaks were type I (graft-related)8 endoleaks
and six were type II (collateral channel-related)
endoleaks. All six type II endoleaks occurred in group
II. Because the endografts were all successfully
deployed in this group, one could question whether
type II endoleaks in these circumstances really consti-
tute a “failure to cure the aneurysm.” It is generally
accepted, however, that type II endoleaks have the
potential to allow an increase in AAA size and to lead
to rupture. In any event, even if these six endoleaks
were discounted from group II, the incidence rate of
endoleak in that group (9.6%) would still exceed the
incidence rate of endoleak in group I (6.6%).
Insufficient attention also has been paid to the
potential for adverse events to occur when there is a
change in type of prosthesis from that previously
used. Even in experienced departments and despite
prolonged instruction and training, technical errors
occur with new equipment. This explains, in part,
why the development of a new prosthesis, no matter
how advanced, will not automatically result in a min-
imization of adverse events.
We conclude from this study that despite improve-
ments in technology and increasing operator experi-
ence, adverse events continue to occur in a relatively
high proportion (45%) of patients who undergo endo-
luminal AAA repair. Reporting the incidence rate of
adverse events provides a more accurate picture of the
morbidity rate of the endoluminal method rather than
simply listing procedures as successes or failures. The
similarity in the incidence rates of adverse events in
patients in group I and group II suggests that there are
inherent risks in the endoluminal method rather than
iatrogenic complications that occur during the learn-
ing curve with a new technique.
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Table VI. Incidence rate of adverse events occurring in two groups of patients who underwent endolumi-
nal abdominal aortic aneurysm repair during two successive periods of time
Group I (n = 75) Group II (n = 115) P value
Perioperative (within 30 days) deaths 4 5.3% 4 3.5% NS
Conversion
Primary 12 16.0% 5 4.3% .007
Secondary 6 8.0% 4 3.5% NS
Supplementary endoluminal repair 7 9.3% 5 4.3% NS
Lower limb ischemia 7 9.3% 17 14.7% NS
Hemodialysis necessitated 3 4.0% 4 3.5% NS
Failure to cure the AAA 5 6.6% 17 14.8% NS
Wound complications 4 5.3% 8 7% NS
Total adverse events 48 64 62 54 NS
Total patients with adverse events 37 49 51 45 NS
AAA, Abdominal aortic aneurysm.
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Dr William J. Quinones-Baldrich (Los Angeles, Calif).
I would like to congratulate Dr May and his associates for
an excellent presentation. I thank the Society for Vascular
Surgery for the opportunity to discuss this important study.
The authors have presented an extensive experience
that consists of 190 patients who underwent endoluminal
repair of abdominal aortic aneurysms over a period of
about 5.5 years. Interestingly, as has occurred in most
series reported to date with endoluminal repair, there were
only 15 females in their series. This politically incorrect mix
underscores the need for miniaturization of these devices
so that they be applicable to situations where access arter-
ies are small.
The authors have divided their experience in two time
periods to attempt to analyze those complications that may
be related to inexperience against those that are inherent in
these procedures. Other than primary conversions, the
author did not note any significant differences between the
two time periods. It is important to note, however, that the
devices used during the two time periods were different. In
the first group, the authors used a combination of the
Parodi, the White-Yu, the Endovascular Technologies, and
the Chuter devices, and in the second group, they used the
Stentor Vanguard for most of the cases, with a few cases
with the Bard, Talent, and AneuRX systems. This, in and
of itself, may help explain why the incidence rate of device-
related complications was similar, given that, during both
periods, there was a significant learning curve specific to
each device used. In addition, the authors tackled more dif-
ficult patient problems in the second group where com-
mon iliac tortuosity greater than 90 degrees was seen in 20
of 95 cases—this was seen in none of the 75 cases in the
first group. In the first group, there was an equal mixture
of tube grafts and bifurcated or aortouniiliac grafts, and in
the second group, most of the grafts were bifurcated.
These differences may help explain why the authors saw a
similar incidence rate of adverse events in both the groups.
There are some important trends that also are noted in
this study. For example, although statistical significance
was not noted in the incidence rate of lower limb ischemia
and failure to cure abdominal aortic aneurysms, in the sec-
ond group, a greater percentage of patients had either an
ischemic complication or an endoleak. On the other hand,
the authors were more successful in the latter part of their
experience in completing the endovascular repair, as is
noted by a decrease in the incidence rate of primary con-
version between the first and second group, which, in fact,
was statistically significant.
In this experience, as reported by Dr May today, and
in others that have been reported thus far, patients that
have persistent endoleaks that lead to rupture of the
aneurysm appear to have some degree of protection from
what is otherwise usually a catastrophic event. In this
series, there were four patients with aneurysm rupture
after an endovascular repair and all survived surgical repair.
This is a consistent finding in other series. Thus, the graft
may actually provide some degree of protection even in
the presence of an endoleak. 
I believe that with the experience reported to date
with endovascular grafts, one can begin to make certain
conclusions in terms of the effectiveness of this approach.
In this regard, the presence of an attachment site endoleak
suggests incomplete protection from the complication of
aneurysm rupture. In fact, aneurysm growth in the pres-
ence of an attachment site endoleak necessitates either
conversion or correction of the endoleak. On the other
hand, failure of the aneurysm to shrink in the absence of a
recognized endoleak is an uncertain result, and thus, con-
tinued observation is necessary. When the aneurysm
shrinks on follow-up, it appears that protection from
aneurysm rupture can be assured. However, continued
observation is necessitated because endoleaks may develop
in patients without previous leaks who had documented
shrinkage of the aneurysm until the time the leak was
developed. In fact, an endoleak that is recognized during
follow-up may be related to aneurysm shrinkage in the
longitudinal dimension. It is in this regard that a fully sup-
ported device may not be able to accommodate this short-
ening, leading to either attachment site or component
junction endoleak. 
Branch flow endoleak, on the other hand, seems to
have a benign course and should be considered separate
from attachment site leaks. Branch flow endoleaks are a
problem inherent to the endovascular approach, and, in
our experience, thromboses are not usually associated with
aneurysm growth.
I agree with the authors’ suggestion that reporting the
incidence rate of adverse events provides a more accurate
picture of the morbidity rate of the endoluminal method,
and I also agree that there are inherent risks in the endo-
luminal methods that are not necessarily iatrogenic com-
plications that occur during the learning curve of these
new techniques. Nevertheless, I cannot help but suggest
that, as we continue to increase our experience with the
endoluminal method and as various groups become famil-
iar with one or two specific devices, some of these inher-
ent risks will decrease in incidence. 
I have four questions for the authors.
First, in the first group, you performed 52 endovascu-
lar grafting procedures with the White-Yu device, and, in
the second group, you used this device on 40 patients. Did
you compare the incidence rate of adverse events between
group 1 and 2 with this one particular device? This perhaps
will give us the best opportunity to test your hypothesis.
Second, it is clear that with the patients in group 2 the
device used was most commonly either bifurcated or aor-
touniiliac. Why the change? And could you speculate as to
how that may have affected the incidence rate of adverse
events as you have reported?
Third, in regards to endoleaks, what is your observa-
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tion comparing attachment site with branch flow endoleak,
looking specifically as it relates to the risk of aneurysm
growth or rupture? 
And finally, because your group has had the opportu-
nity to use different devices, what is your experience com-
paring fully supported component type and unitary non-
supported devices as to their ability to tolerate dimension-
al changes in the aneurysm during the follow-up period? 
I truly appreciate the opportunity the Society has
given me to discuss this excellent paper and congratulate
the authors on an outstanding presentation. 
Dr James May. Thank you for those thoughtful com-
ments. There were fewer adverse events in the patients in
group 2 with White-Yu as compared with group 1, but not
significantly so. And it is probably important to point out
that there was a disproportionately large number of tube
grafts in that subset in group 1 and a disproportionately
large number of bifurcated grafts in the subset in group 2.
So, that the comparison is not as clean as you might like it
to be.
Your second question related to why we changed to
bifurcated and aortoiliac grafts. That was because we had
seen progressive failure in the tube endografts in the mid-
term follow-up period. The Kaplan-Meier curves for bifur-
cated and aortoiliac endografts were relatively horizontal,
but the curve for a tube endograft was well below 50% at
3 years, so that was the basis of that.
Your third question was in relation to type 1 and type
2 endoleaks and their relationship to rupture. All four
patients with rupture in our experience had the type 1 or
attachment endoleaks.
You also asked about the relationship of these two
types of endoleaks to the growth of the aneurysm. There
is no question that in type 1 the aneurysms grow—I think
a number of us have documented that—but our experi-
ence with the type 2 or collateral channel endoleaks has
really been too recent to comment usefully on that.
And finally, your question about the ability of unsup-
ported versus supported endografts to accommodate to the
shrinkage that we see longitudinally and transversely in suc-
cessfully treated endografts I think is a very interesting
question. And you may well be right that the unsupported
ones have an advantage in that direction. Unfortunately,
we have so few unsupported grafts that I do not think that
I could usefully comment on our experience there, but
thank you again for your questions.
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